Overall, in view of the observations of TB re-activation after anti-TNF-α therapy, on the one hand, and anti-PD-1 therapy, on the other, it appears that a window of protective immunity exists in humans, sitting in between two extremes of insufficient and excessive T-cell immunity [180]. This evidence concerns the gene PDCD1 and tuberculosis.